Surrogate Endpoints: How to Choose the Best One for Your Rare Disease Trial
XTalks
SEPTEMBER 17, 2020
Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Novartis’ Signifor (pasireotide) is also indicated in the treatment of the disease.
98 
Let's personalize your content